At Rare Disease Watch, accuracy, clarity, and integrity guide every piece of content we publish. Rare diseases affect millions of individuals and families worldwide, and our responsibility is to provide information that is reliable, accessible, and genuinely useful. These editorial standards outline how we work, how we verify our reporting, and how we maintain trust with our readers.
Our purpose is to deliver clear and timely reporting on developments that shape the rare disease landscape. This includes advances in research, clinical insights, regulatory activity, policy updates, funding opportunities, and treatment progress. We translate complex scientific and medical information into accessible content without losing precision, so that professionals, patients, advocates, and families can make sense of what is changing and why it matters.
Every article is based on verifiable, credible, and traceable sources. Our editors and contributors follow a rigorous process to ensure accuracy:
We do not publish unverified claims or speculative material. When reporting on emerging research, we clearly explain what is known, what is preliminary, and what requires further investigation.
We rely on trusted and internationally recognised bodies, including but not limited to:
All content is grounded in transparent, reputable sources.
AI may be used to support aspects of the editorial process, including:
• drafting support
• formatting and structure
• readability improvements
• SEO optimisation
• summarisation assistance
• workflow and research support
However, all published content is reviewed, verified, edited, and approved by a human contributor. Responsibility for the accuracy, quality, context, and integrity of published material always remains with the human author and editorial team.
AI is used as a support tool, not as a substitute for editorial judgement, scientific scrutiny, or ethical responsibility.
Editorial independence is central to our work. Our contributors do not accept incentives or direction from pharmaceutical companies, advocacy groups, or commercial partners in relation to the content we produce. If a potential conflict arises, it is openly disclosed and the contributor is removed from involvement in that particular article.
Commercial arrangements or advertising do not influence our reporting.
Science and medicine evolve rapidly, and accuracy must evolve with them. If an error appears, we correct it promptly and transparently.
Our correction process includes:
When new data or regulatory decisions emerge, articles may be updated to reflect the latest understanding.
Rare Disease Watch is committed to being a dependable daily source for rare disease news and insight. These standards help ensure that our readers can trust the information they receive and understand how we work behind the scenes. Our goal is not simply to report what is happening, but to help the rare disease community stay informed with confidence and clarity.
